A 96-well DNase I footprinting screen for drug-DNA interactions.
The established protocol for DNase I footprinting has been modified to allow multiple parallel reactions to be rapidly performed in 96-well microtitre plates. By scrutinizing every aspect of the traditional method and making appropriate modifications it has been possible to considerably reduce the time, risk of sample loss and complexity of footprinting, whilst dramatically increasing the yield of data (30-fold). A semi-automated analysis system has also been developed to present footprinting data as an estimate of the binding affinity of each tested compound to any base pair in the assessed DNA sequence, giving an intuitive 'one compound-one line' scheme. Here, we demonstrate the screening capabilities of the 96-well assay and the subsequent data analysis using a series of six pyrrolobenzodiazepine-polypyrrole compounds and human Topoisomerase II alpha promoter DNA. The dramatic increase in throughput, quantified data and decreased handling time allow, for the first time, DNase I footprinting to be used as a screening tool to assess DNA-binding agents.
Ellis
Tom
T
Spirogen Ltd, London Bioscience Innovation Centre, London, UK.
Evans
David A
DA
Martin
Christopher R H
CR
Hartley
John A
JA
D000951:Antigens, Neoplasm / Q000235:genetics; D001569:Benzodiazepines / Q000737:chemistry; D018983:DNA Footprinting / Q000295:instrumentation / Q000379:methods*; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D003850:Deoxyribonuclease I; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D007259:Infrared Rays; D011401:Promoter Regions, Genetic; D011758:Pyrroles / Q000737:chemistry
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D011758:Pyrroles; D001569:Benzodiazepines; D003850:Deoxyribonuclease I; D004250:DNA Topoisomerases, Type II